Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.medscape.com/viewarticle/991112
0
0
Early Anti-VEGF Isn't Worth Cost in Diabetic Retinopathy - Medscape
4/25/23 at 5:23pm
Organization
Medscape
Author
Donavyn Coffey
Details
25 words
Summarize
Health Conditions
Health
Vision Care
Worth Cost
Diabetic Retinopathy
Medscape
vision outcomes
A drug tested on patients with nonproliferative diabetic retinopathy did not improve vision outcomes.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...